Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
January 08, 2026 | Source: Jasper Therapeutics, Inc.
Overview of Briquilimab's Efficacy in Clinical Trials
Jasper Therapeutics, Inc. (Nasdaq: JSPR), a pioneering biotechnology firm, has announced promising results from the updated clinical data regarding briquilimab, a novel antibody therapy aimed at treating chronic spontaneous urticaria (CSU) and other mast cell-driven diseases. The data stems from the BEACON Phase 1b/2a study and the subsequent open-label extension study. These findings emphasize briquilimab's potential for rapid and durable disease control among adult patients.
Key Findings from the BEACON Study
The BEACON study, a randomized, double-blind, placebo-controlled trial, assessed the efficacy of multiple ascending doses of subcutaneous briquilimab among patients suffering from moderate to severe CSU. The updated results reveal:
- 67% of additional patients (n=6) achieved a complete response at 12 weeks.
- Mean UAS7 (Urticaria Activity Score over 7 days) reduction of 31 points.
- 83% of participants saw a complete response by week 3.
Dr. Daniel Adelman, Acting Chief Medical Officer of Jasper, expressed satisfaction with these results, noting that they reaffirm briquilimab's potential to deliver effective disease control quickly. "These results underscore our commitment to providing effective therapies for patients grappling with chronic urticaria," he stated.
Open Label Extension Study Results
The open-label extension study enrolled participants from both the BEACON study and the SPOTLIGHT study. Key findings include:
- 58% of CSU patients (n=36) achieved a complete response at 12 weeks.
- 75% of CSU participants attained either a complete response or well-controlled disease (UAS7 ≤ 6).
- In the CIndU segment, 65% of patients (n=17) achieved a complete or partial response by week 16.
These encouraging results showcase briquilimab's ability to produce significant improvements in disease management while maintaining a favorable safety profile.
Safety Profile and Future Developments
The safety observations from the BEACON and open-label extension studies indicate that briquilimab is well-tolerated, with no dose-limiting toxicities reported. Adverse events related to KIT blockade were largely low-grade and transient. With a median follow-up duration exceeding 200 days, the data supports the advancement of briquilimab to a Phase 2b study, slated for the second half of 2026.
Jeet Mahal, President and CEO of Jasper, expressed enthusiasm about the potential pathways the data opens up for the company: “Our findings highlight briquilimab's ability to provide rapid disease control and sustained efficacy, fulfilling unmet medical needs for patients with chronic urticaria.”
Upcoming Conference and Webinar
Jasper Therapeutics will host a conference call and webinar today at 8:00 a.m. ET, featuring a live Q&A session with management following the presentation. For those unable to attend, a link to the archived webcast and presentation materials will be made available on the Jasper Investor Relations website.
About Jasper Therapeutics
Jasper Therapeutics is committed to developing innovative treatments for mast cell-driven diseases. Briquilimab, its flagship therapy, serves to inhibit signaling through the cell surface receptor KIT, which is crucial for the survival of mast cells. This therapeutic approach aims to address chronic urticaria and associated conditions effectively.
For further insights into their research and advancements, visit www.jaspertx.com.